Metropolis Healthcare
Working at Metropolis Healthcare
Company Summary
Overall Rating
3% above
Highly rated for
Skill development, Job security, Company culture
Critically rated for
Promotions
Work Policy
Top Employees Benefits
About Metropolis Healthcare
Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The Company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services.
With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry.
Metropolis Healthcare Ratings
Overall Rating
Category Ratings
Skill development
Job security
Company culture
Work-life balance
Work satisfaction
Salary
Promotions
Work Policy at Metropolis Healthcare
Metropolis Healthcare Reviews
Top mentions in Metropolis Healthcare Reviews
Compare Metropolis Healthcare with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 4.1/5 based on 815 reviews | 3.5/5 based on 915 reviews | 4.1/5 based on 1.1k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Job security Company culture | No highly rated category | Skill development Work-life balance Company culture | Skill development Work-life balance Salary |
Critically Rated for | Promotions | Promotions Job security Salary | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 81% employees reported | Work from office 73% employees reported | Work from office 82% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 244 women | 3.6 Good rated by 179 women | 3.8 Good rated by 253 women | - no rating available |
Rating by Men Employees | 4.2 Good rated by 504 men | 3.5 Good rated by 661 men | 4.2 Good rated by 685 men | - no rating available |
Job security | 3.9 Good | 3.1 Average | 3.8 Good | 4.0 Good |
Metropolis Healthcare Salaries
Scientific Officer
Lab Technician
Phlebotomist
Senior Scientific Officer
Medical Laboratory Technician
Area Sales Manager
Territory Sales Manager
Executive Accountant
Consultant Pathologist
Regional Sales Manager
Metropolis Healthcare Interview Questions
Interview questions by designation
Top Metropolis Healthcare interview questions and answers
Metropolis Healthcare Jobs
Metropolis Healthcare News
AI vision startup Metropolis is buying Oosto (formerly known as AnyVision) for just $125M, sources say
- AI vision startup Metropolis is acquiring Oosto (formerly known as AnyVision) for $125 million, a significant drop from its previous valuation and funding of $380 million.
- Oosto, previously known as AnyVision, faced controversies related to surveillance applications and data collection, which resulted in the loss of Microsoft as an investor.
- Metropolis focuses on AI-powered parking systems and aims to expand its offerings through the acquisition of Oosto, a computer vision and security solutions company.
- The acquisition highlights the challenges faced by AI startups and the impact of timing in an evolving AI industry.
Metropolis - Core Diagnostics Acquisition At Attractive Price, Synergies May Take Time: ICICI Securities
- ICICI Securities maintains Add rating on Metropolis with higher target price of Rs 2,335.
- Synergies from Metropolis - Core Diagnostics acquisition may take time.
Stocks that will see action today: December 10, 2024
- Patanjali Foods Ltd fined ₹1 lakh for violating ground water regulations.
- Tiger Logistics approves proposal to raise ₹400 crore via preferential issue.
- Torrent Power's ₹3,500 crore QIP issue oversubscribed four times.
- Metropolis Healthcare to acquire Core Diagnostics for ₹247 crore.
Metropolis Healthcare buys Core Diagnostics, enhances its cancer testing footprint
- Metropolis Healthcare acquires Core Diagnostics to enhance its cancer testing footprint.
- Metropolis aims to offer advanced cancer testing nationwide to address the critical need.
- The acquisition provides Metropolis with greater access to the Northern and Eastern regions of India.
- The deal involves acquiring 100% stake in Core Diagnostics through a combination of cash and stock.
Metropolis Healthcare To Acquire Core Diagnostics For Rs 247 Crore
- Metropolis Healthcare Ltd. is set to acquire Core Diagnostics for a total of Rs 246.8 crore.
- The acquisition will be executed through a combination of cash and stock, with 55% being cash and 45% as an equity swap.
- The deal is expected to be completed within 60 days and will make Metropolis Healthcare the leading cancer testing company in India.
- The move will enhance Metropolis Healthcare's cancer testing capabilities and strengthen its presence in northern and eastern regions of India.
Metropolis Healthcare acquires Core Diagnostics for Rs 246.8 Cr
- Metropolis Healthcare has acquired Core Diagnostics for Rs 246.8 crore.
- The acquisition will be financed through a combination of cash and stock.
- Metropolis aims to expand its advanced cancer testing capabilities and market presence in northern and eastern India.
- Core Diagnostics operates across 200 cities in India and registered revenue of Rs 110 crore in FY23-24.
Jupiter Lifeline, Metropolis, Thyrocare Remains ICICI Securities' Top Picks In Healthcare Sector; Know Why
- ICICI Securities has identified Jupiter Lifeline, Metropolis, and Thyrocare as its top picks in the healthcare sector.
- Network expansion is a priority for most hospital chains, but ICICI Securities believes KIMS and Jupiter Lifeline are better positioned among them.
- NDTV Profit's special research section compiles quality research reports from top brokerages and research agencies, offering subscribers an opportunity to expand their understanding of companies and sectors.
- Subscribers to NDTV Profit get access to exclusive stories, newsletters, research reports, and special events.
Metropolis Healthcare Confident Of Achieving 13–15% Revenue Guidance
- Metropolis Healthcare CEO confident of achieving 13–15% revenue growth guidance.
- Revenue from operations rose 13.4% to Rs 349.8 crore in Q2FY25.
- Net profit increased 31% to Rs 46.7 crore in the September quarter.
- CEO attributes growth to expansion efforts in B2C operations, tier 3, TruHealth, and speciality portfolios.
Aurobindo Pharma, Shree Cement, Star Cement, Ramco Cements, Metropolis, GSPL Q2 Result Review: HDFC Securities
- HDFC Securities has reviewed the Q2 results of Aurobindo Pharma, Shree Cement, Star Cement, Ramco Cements, Metropolis, and GSPL.
- The brokerage maintains an 'Add' rating on Aurobindo Pharma and Shree Cement.
Compare Metropolis Healthcare with
Contribute & help others!
Companies Similar to Metropolis Healthcare
Metropolis Healthcare FAQs
Reviews
Interviews
Salaries
Users/Month